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Abstract Chronic migraine (CM) prevalence ranges
around 1–5%. Most of these patients usually treat their
acute attacks with triptans, whose efficacy is extremely
variable. A genetic basis for migraine is evident and many
susceptibility genes have been described, as well as gene
polymorphisms possibly implied in therapy response.
Several factors could be involved in the evolution of epi-
sodic migraine into a chronic form, such as natural history,
psychiatric comorbidity, and the individual’s response to
therapy. During a study aimed at detecting connections
between genotype and response to triptans administration,
we characterized a CM population for polymorphisms in
the genes coding for monoamine oxidase A, g-protein beta
3 and the cytochromes CYP3A4 and CYP1A2. Alleles and
genotypes distributions were compared with known fre-
quencies of healthy Caucasian populations. A significant
association with CM was found for the long allele of
monoamine oxidase A 30 bp VNTR and CYP1A2*1F
variant. Such genomic analysis is part of an integrated
platform able to evaluate different levels of metabolic
pathways of drugs in CM and their influence in the
chronicization process.
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Introduction
The definition of chronic migraine (CM) is still debated
[1, 2], although its prevalence ranges around 1–5% [3] and
its management requires specific skills, being headaches
that are most difficult to treat.
Triptans are mainly used for the acute treatment of CM
attacks and share a similar mechanism of action, based on
the stimulation of serotonin receptors (5HT1B/1D), yet their
therapeutic benefits are largely variable among different
subjects. Different metabolic rates may probably account
for different levels of drug response. Enzymes belonging to
the cytochrome P450 superfamily are the central metabo-
lizer of eletriptan, frovatriptan and naratriptan, while the
monoamine oxidase MAO A is the main metabolizing
enzyme for sumatriptan and rizatriptan. The two systems
cooperate in metabolism of almotriptan (MAO A and CYP
3A4) and zolmitriptan (MAO A, CYP 1A2 and CYP3A4)
[4]. Several SNPs in these genes are related to alteration
of enzymatic activity and genotypization can thus con-
tribute to select the most adequate class of triptan to be
administered.
Polymorphisms in genes involved in transduction signal
via the 5HT1B/1D receptor, as the C825T SNP in the gene
coding the G protein b3 subunit (GNB3), can also be
important determinants of triptan therapy outcome [5].
In the framework of a study aimed at identifying a
correlation between triptans response and individual
genetic profile, we characterized a panel of gene SNPs
involved in triptans pharmacokinetics and pharmacody-
namics in a CM population.
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Patients and methods
Description of analyzed populations
A total of 104 patients (12 males 92 females) affected with
CM, aged 25–81, were enrolled in the study. All patients
were referred to the Regional Referral Headache Centre of
2nd School of Medicine of Sapienza University at San-
t’Andrea Hospital in Rome, Italy. The diagnosis of CM
was performed accordingly to 2006 ICHD-II revised rules
[1]. The study received the approval of the University Ethic
Committee. All patients signed a written consent before the
enrolment in the study.
Genetic analysis
We studied the following DNA polymorphisms: an
untranslated variable number of tandem repeats (uVNTR)
of 30 basepairs located about 1.1 kb upstream of the ATG
initiation codon of monoamine oxidase A (MAO A) gene;
a A ? C substitution and at position -163 and a G ? A
transition at position -3860 in the 50noncoding region of
the CYP1A2 gene, indicated as *1F allele (rs762551) and
*1C allele (rs2069514), respectively; an A ? G transition
at position -392 in the promoter region of CYP3A4 gene,
indicated as *1B allele (rs2740574) and a C ? T transition
at nucleotide 825 (rs5443) in the coding sequence of G
protein b3 subunit (GNB3) gene which produces a trun-
cated form of the protein.
Genomic DNA was isolated from peripheral blood using
the X-tractor Gene system (Corbett Life Science, Australia).
The MAO A promoter region polymorphism was gen-
otyped on the basis of previously described method [6].
Identification of the amplified fragments size was per-
formed by microchannel electrophoresis on chip, using the
Agilent 2100 Bioanalyzer system (Agilent Technologies,
Santa Clara, CA, USA).
All the single nucleotide polymorphisms were geno-
typed by pyrosequencing technology (Pyrosequencer Py-
roMark ID system–Biotage AB and Biosystems, Uppsala,
Sweden). Forward, reverse and sequencing primers were
obtained by PSQ Assay Design software (Biotage AB and
Biosystems, Uppsala, Sweden). PCR primer pairs and
sequencing primer for each SNP are reported in Table 1.
Briefly, regions covering the SNP of interest were
amplified as follows: after initial denaturation (95C,
10 min), a thermal cycler protocol (35 cycles) was employed
cycling 20 s at 95C, 20 s at 48C, followed by 30 s exten-
sion at 72C; a final extension of 5 min at 72C was added.
All PCR reactions were performed in a final volume of 50 ll
containing 40 ng of genomic DNA, 10 pmol of each primer,
0.2 mL dNTPs, the appropriate concentration of MgCl2
(Table 1), PCR buffer and 1 U of Taq DNA polymerase
(Takara Bio Inc., Otsu, Japan).
Single-stranded DNA was isolated from the PCR reac-
tion using the Pyrosequencing Vacuum Prep Workstation
(Biotage) and Streptavidin Sepharose TM High Perfor-
mance beads (Amersham Biosciences, Uppsala, Sweden)
that bind to the biotinylated primer. After washing in 70%
ethanol, incubation in denaturing buffer and flushing
with wash buffer, the beads were then released into a
96-well plate containing annealing buffer and the specific
sequencing primer. Annealing was performed at 80C for
2 min followed by cooling at room temperature. Then real-
time sequencing was performed.
Statistical analysis
Chi-square Hardy–Weinberg equilibrium (HWE) test cal-
culator for biallelic markers available at http://www.oege.
org/software/hwe-mr-calc.shtml [7] was used to test for
deviations of genotype frequencies from HWE. The geno-
type and allelic distributions in the migraine population
were compared with those reported in literature for healthy
Caucasian subjects.
In the case of the X-linked MAO A uVNTR polymor-
phism, male patients (12 out of 104 total subjects) were
excluded from statistical analysis.
Genotypic and allelic frequencies among the different
groups were compared using Chi-square analysis. Values
of P \ 0.05 were considered significant.
Results
All the polymorphisms analyzed were in Hardy–Weinberg
equilibrium. Frequencies of GNB3 C825T, CYP3A4*1B
and CYP1A2*1C SNPs in CM population do not differ
Table 1 Primers and Mg2? concentrations for PCR amplification and pyrosequencing
SNPs Forward primer (50–30) Reverse primer (50–30) Sequencing primer (50–30) Mg2? concentration (mM)
CYP1A2*1C CTTCTTGGATGCTTATGA aTGTAATTCCAGCTACTCG ACCGCAACCTCCGCC 1
CYP1A2*1F aAGTGGAAACTGAGATGAT ATACCAGAAAGACTAAGC CTACCATGCGTCCTG 1
CYP3A4*1B GGGATGAATTTCAAGTAT aGGGTTCTTATCAGAAACT CAGCCATAGAGACAAGG 1
GNB3 C825T ACGAGAGCATCATCTG aATGGAGTCCCAGACAT ATCTGCGGCATCACG 1.5
a Biotin molecule attached
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from those reported in literature for healthy Caucasian
subjects [8–10]. Pertaining to GNB3 C825T SNP, there are
50 (48%) homozygous noncarriers of the mutated 825T
allele, 42 (40.4%) heterozygous carriers and 12 (11.5%)
homozygous carriers of the mutated 825T allele in our
study population.
As regards CYP3A4 -392A [ G SNP, only 4 (3.8%)
heterozygous carriers of the mutated G allele were found;
the remaining 100 CM patients (96.2%) were homozygous
noncarriers of the mutated variant. About CYP1A2, there
are 99 (95.2%) homozygous noncarriers of *1C allele and 5
(4.8%) heterozygous carriers of the mutated -3860A
allele.
Concerning the MAO A uVNTR polymorphism, the 3R,
4R and 5R genetic variants are present in our population.
The 3R and 4R alleles account for the 98% of the total,
according to literature reports [11] but their frequencies are
significantly different in our migraine population compared
with the Italian healthy population previously reported [3].
The 3R variant is under-represented (29.8 vs. 42.2%) and
the 4R variant is over-represented (67.9 vs. 55%) in CM as
reported in Table 2.
A significant difference in frequency distributions was
also found for the CYP1A2*1F. In detail, the CYP1A2*1F
allele is over-represented in CM (47.1 vs. 31%). There are
34 (32.7%) homozygous noncarriers of the mutated -163C
allele, 42 (40.4%) heterozygous carriers and 28 (26.9%)
homozygous carriers of the mutated -163C allele
(Table 3).
Discussion
We designed a study to characterize potential association
between genotype and triptans response in CM, aimed to
assign a targeted therapy according to the metabolic class
(based on genotype) of the CM patients. Here, we present
the results of the preliminary genetic characterization of a
population of 104 CM patients.
Genotyping of single nucleotide polymorphisms was
performed by pyrosequencing technology, a modern plat-
form able to provide fast, accurate and reliable qualitative
sequencing data simultaneously with quantitative allele
frequency information, for up to 96 samples in one step.
Genotyping for CYP1A21F is reported in Fig. 1.
On the basis of our analysis, neither GNB3 and CYP3A4
SNPs nor CYP1A2*1C variant seems to be implicated in
the genetic liability to CM, whereas an association was
found for MAO A and CYP1A2*1F polymorphisms.
Monoamine oxidase A is the metabolic enzyme of
neurotransmitters and the uVNTR polymorphism located in
its promoter affects its transcriptional activity modulating
the levels of monoamines. In detail, enzyme expression
is relatively high for carriers of 3.5 or 4 repeats (MAO
Table 2 Allelic frequencies of
MAO A uVNTR polymorphism
in controls (Data from Deckert
et al. [6]) and chronic migraine
df degrees of freedom










2R 0 2 (1.4) 8.39 (0.039)
df = 3
3R 55 (29.9) 59 (42.2)
4R 125 (67.9) 77 (55)
5R 4 (2.2) 2 (1.4)
Table 3 Genotypic and allelic
frequencies of CYP1A2
-163A [ C SNP in controls
(Data from Skarke et al. [20])
and chronic migraine
df degrees of freedom











CC 28 (26.9) 44 (8.9) 27 (\0.00001)
df = 2
CA 42 (40.4) 227 (45.9)
AA 34 (32.7) 224 (45.2)
Alleles
C 98 (47.1) 315 (31) 17.8 (\0.00001)
df = 1
A 110 (52.9) 675 (69)
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A-high) and lower for carriers of 2, 3, or 5 repeats (MAO
A-low) [9, 12]. To better discriminate 15–30 bp length
differences, PCR fragments’ size was determined by the
Bioanalyzer platform, a more sensitive and accurate method
than the classical agarose/acrylamide gel electrophoresis
(Fig. 2). Our data indicate an over-representation of the
MAO A-high form in migraineurs. The functional effect of
this variant is an increased MAO A activity which, leading to
hypermetabolism of amine neurotransmitters, might cause a
lower level of serotonin, a condition often described in
association with migraine pathophysiology [13].
The cytochrome P450 enzyme CYP1A2 plays a main
role in the metabolism of a variety of structurally unrelated
compounds, including a broad range of different drugs and
its activity is widely modulated by a plethora of inducer/
inhibitor molecules. As the other members of the cyto-
chrome P450 superfamily, CYP1A2 gene is highly poly-
morphic and the *1C and the *1F alleles are associated
with reduced metabolic activity [14, 15]. We found a sig-
nificant over-representation of the *1F variant in migrai-
neurs. An involvement of *1F allele has been described in
various unrelated pathologies [16, 17] and its effect on the
enzymatic activity and inducibility of cytochrome has been
mainly studied in relation with smoking, a main known
inducer of cytochrome.
A more comprehensive analysis is required to elucidate
the effective functional link between *1F variant and
migraine, taking into account physiological, environmental
and lifestyle factors affecting both CYP P450 phenotype
and the manifestation of migraine pain.
The potential of MAO A and CYP 1A2 polymorphisms
as susceptibility factors for migraine should be further
addressed in light of the known implication of these genes
in metabolism of triptans, especially in the case of zolmi-
triptan, which undergoes a two-step catabolism: an active
metabolite is produced by CYP1A2 (more stable and active
of the parent compound) and successively degraded by the
MAO A activity [18]. Therefore, the study of functional
interaction between CYP and MAO A SNPs might be of
striking impact for tailored drug selection [19]. The pos-
sibility to define a specific metabolic background respon-
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Sequence to analyze:  
G/TGCCCACAGAGCT
Sequence to analyze:  
G/TGCCCACAGAGCT
Fig. 1 Genotyping of CYP1A2*1F by pyrosequencing technology
based on the sequencing-by-synthesis method. The sequence of
interest is analyzed by the instrument which produces a graphic
(pyrogram) reporting the nucleotides inserted in the fragment of DNA
synthesized. Reverse-complement sequence has been analyzed.
Theoretical pyrograms are reported (left panel). The observed
sequences are shown in the right. Region including the SNP of
interest is highlighted in yellow
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the use (misuse ? abuse) of such drugs in a pre-defined
nonresponders’ population of migraine patients, avoiding
one of the most important factors in the chronicization
progress towards CM, such as triptans abuse. The next
steps in the research area of CM determinants should
include pharmacogenomics for the definition of the
responders’ patients to specific known drugs, such as
triptans [20–22] as well as the application of these methods
in testing new active compounds for migraine [23, 24].
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